A Phase II Trial of Erlotinib Plus Bevacizumab in Advanced Hepatocellular Carcinoma as a Second-line Therapy in Patients Who Have Progressed Despite First-line Sorafenib Therapy (AVF4572).

Trial Profile

A Phase II Trial of Erlotinib Plus Bevacizumab in Advanced Hepatocellular Carcinoma as a Second-line Therapy in Patients Who Have Progressed Despite First-line Sorafenib Therapy (AVF4572).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Oct 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Primary endpoint has been met. (Number of Patients with Progression Free Survival (PFS) at 16 weeks), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top